Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
139
Views
0
CrossRef citations to date
0
Altmetric
Case Report

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report

Liting ChenDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Bin XuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Wanying LiuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Di WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Jinhuan XuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Xia MaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Min XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
,
Jianfeng ZhouDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaView further author information
&
Yi XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 361-366 | Published online: 08 Apr 2022

References

  • Carter JC, Sheehan DW, Prochoroff A, Birnkrant DJ. Muscular Dystrophies. Clin Chest Med. 2018;39(2):377–389. doi:10.1016/j.ccm.2018.01.004
  • Mercuri E, Bonnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394(10213):2025–2038. doi:10.1016/S0140-6736(19)32910-1
  • Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013;381(9869):845–860. doi:10.1016/S0140-6736(12)61897-2
  • Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687–695. doi:10.1016/S0140-6736(02)07815-7
  • Emery AE. Fortnightly review: the muscular dystrophies. BMJ. 1998;317(7164):991–995. doi:10.1136/bmj.317.7164.991
  • Sarkozy A, Foley AR, Zambon AA, Bonnemann CG, Muntoni F. LAMA2-related dystrophies: clinical phenotypes, disease biomarkers, and clinical trial readiness. Front Mol Neurosci. 2020;13:123. doi:10.3389/fnmol.2020.00123
  • Burkin DJ, Kaufman SJ. The α7β1 integrin in muscle development and disease. Cell Tissue Res. 1999;296(1):183–190. doi:10.1007/s004410051279
  • Hu P, Yuan L, Deng H. Molecular genetics of the POMT1-related muscular dystrophy-dystroglycanopathies. Mutat Res Rev Mutat Res. 2018;778:45–50. doi:10.1016/j.mrrev.2018.09.002
  • Caggiano S, Khirani S, Dabaj I, et al. Diaphragmatic dysfunction in SEPN1-related myopathy. Neuromuscul Disord. 2017;27(8):747–755. doi:10.1016/j.nmd.2017.04.010
  • Puckelwartz M, McNally EM. Emery-Dreifuss muscular dystrophy. Handb Clin Neurol. 2011;101:155–166.
  • Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2010;20(7):471–475. doi:10.1016/j.nmd.2010.04.007
  • Uotani H, Hirokawa S, Saito F, et al. Non-Hodgkin’s lymphoma of the ascending colon in a patient with becker muscular dystrophy: report of a case. Surg Today. 2001;31(11):1016–1019. doi:10.1007/s005950170015
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. doi:10.1016/S1470-2045(18)30864-7
  • Locke FL, Miklos DB, Jacobson CA, et al. Investigators and contributing kite members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–654.
  • Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022;386(7):629–639. doi:10.1056/NEJMoa2116596
  • Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood. 2020;135(1):17–27. doi:10.1182/blood.2019000017
  • Cardenas AM, Gonzalez-Jamett AM, Cea LA, Bevilacqua JA, Caviedes P. Dysferlin function in skeletal muscle: possible pathological mechanisms and therapeutical targets in dysferlinopathies. Exp Neurol. 2016;283:246–254. doi:10.1016/j.expneurol.2016.06.026
  • Han R. Muscle membrane repair and inflammatory attack in dysferlinopathy. Skelet Muscle. 2011;1(1):10. doi:10.1186/2044-5040-1-10
  • Sharma A, Yu C, Leung C, et al. A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis. Arterioscler Thromb Vasc Biol. 2010;30(11):2196–2204. doi:10.1161/ATVBAHA.110.208108
  • Han R, Campbell KP. Dysferlin and muscle membrane repair. Curr Opin Cell Biol. 2007;19(4):409–416. doi:10.1016/j.ceb.2007.07.001
  • Aoki M, Takahashi T. [Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)]. Rinsho Shinkeigaku. 2005;45(11):938–942. Japanese.
  • Cao XQ, Joypaul K, Cao F, Gui LL, Hu JT, Mei W. Anesthetic management of a patient with limb-girdle muscular dystrophy 2B:CARE-compliant case report and literature review. BMC Anesthesiol. 2019;19(1):155. doi:10.1186/s12871-019-0813-8
  • Aldosari KH, Al-Ghamdi S, Alkhathlan KM, Alkhalidi HM. Phenotypic and genotypic analysis of limb-Girdle muscular dystrophy type 2B. Neurosciences. 2020;25(3):214–217. doi:10.17712/nsj.2020.3.20200002
  • Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729
  • Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–1226. doi:10.1158/2159-8290.CD-18-0442

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.